|Articles|November 19, 2010

Reassessing the Stroke Prevention Paradigm: Evolving Strategies for Managed Care of Patients With At
Volume 16
Issue 10 Suppl

Reassessing the Stroke Prevention Paradigm: Evolving Strategies for Managed Care of Patients With Atrial Fibrillation

Download PDF: Reassessing the Stroke Prevention Paradigm: Evolving Strategies for Managed Care of Patients With Atrial Fibrillation

Articles in this issue

over 15 years ago

Article

New Options for Stroke Prevention in Atrial Fibrillation

over 15 years ago

Article

A Pharmacoeconomic Perspective on Stroke Prevention in Atrial Fibrillation

over 15 years ago

Article

Finding a Balance in Long-Term Anticoagulation Therapy

over 15 years ago

Article

Participating Faculty and CME Information

over 15 years ago

Article

An Overview of Stroke and the Impact of Atrial Fibrillation

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

June 8th 2026

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

Health Care Utilization in Veterans With Alzheimer Disease

ByYing Wang, PhD,Byron J. Aguilar, PhD,Mingfei Li, PhD,Peter Morin, MD, PhD,Joel Reisman, BS,Wen Hu, MS,Jong Soo Lee, PhD,Dan Berlowitz, MD, MPH,Qinqing Li, MS,Raymond Zhang, PhD,Amir Abbas Tahami Monfared, MD, PhD,Quanwu Zhang, PhD,Weiming Xia, PhD

June 4th 2026

Health care costs | Image Credit: © Valeri Luzina - stock.adobe.com

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

ByPooja Chandrashekar, MD, MBA,Sachin H. Jain, MD, MBA

June 4th 2026

Real-World Weight Loss With Injectable Semaglutide vs Dulaglutide for Diabetes

ByAllison Spitery, PharmD, BCACP,Alison Lobkovich, PharmD, BCACP,Emily Thomas, PharmD, BCPS, BCACP

June 4th 2026

Reassessing the Stroke Prevention Paradigm: Evolving Strategies for Managed Care of Patients With Atrial Fibrillation

Articles in this issue

Related Content

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Health Care Utilization in Veterans With Alzheimer Disease

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

Real-World Weight Loss With Injectable Semaglutide vs Dulaglutide for Diabetes

Trending on AJMC

Survodutide Phase 3 Data Signal Metabolic Gains Beyond Weight Loss

Measles Cases Climb to 2000 in the US, Increasing Cases Year Over Year

Emerging Data Suggest Survodutide Targets Liver Fat More Rapidly Than Weight Loss: Lee Kaplan, MD, PhD

Oral Orforglipron Added to Basal Insulin Cuts HbA1c in Type 2 Diabetes

Nutrition in Pregnancy May Shape Metabolic Health After Delivery